Simon Sutcliffe
Chairman at PREMIER DIVERSIFIED HOLDINGS INC.
Profile
Simon Sutcliffe is currently the Chief Executive Officer & Director at Premier Diagnostic Center (Vancouver), Inc. and Initio Medical Group, Inc. He is also the Independent Chairman at Premier Diversified Holdings, Inc. since 2014 and the Chief Medical Officer & Vice Chairman-Societal at Omnitura Therapeutics, Inc. since 2009.
Additionally, he serves as the Chairman of the Institute for Health System Transformation & Sustainability, Director of Bold Therapeutics, Inc., President of the International Cancer Control Congress Association, President-Canada Region of the International Network For Cancer Treatment & Research, Chief Medical Officer of Qu Biologics, Inc., and Principal of Cci Cancer Control, Inc.Dr. Sutcliffe's former positions include President & Chief Executive Officer of BC Cancer Agency from 2000 to 2009, President & Chief Executive Officer of Princess Margaret Hospital from 1994 to 1996, and President & Chief Executive Officer of Ontario Cancer Institute from 1994 to 1996.
He was also the Chairman of the Michael Smith Foundation for Health Research in 2006-2007 and the Canadian Partnership Against Cancer Corp.
from 2009 to 2012.
He has also served as a Director at Genome British Columbia and as a Professor at the University of Toronto.
Dr. Sutcliffe was the President of the British Columbia Cancer Foundation in 2008.
Dr. Sutcliffe obtained his doctorate degree from St Bartholomew's Hospital Medical College in 1970.
Simon Sutcliffe active positions
| Companies | Position | Start |
|---|---|---|
| PREMIER DIVERSIFIED HOLDINGS INC. | Chairman | 2014-07-23 |
Omnitura Therapeutics, Inc.
 Omnitura Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Omnitura Therapeutics, Inc. is a biopharmaceutical company engaged in the commercialization of Multifunctional Multitargeted pharmaceuticals for oncology, a new class of therapies that is design to address the fundamentally complex and heterogeneous nature of cancer. The firm's product Aneustat, is a non-toxic, orally delivered, multivalent I-O drug candidate design to intercept, treat, and prevent cancer. The company was founded by James Dao and Jeffrey Dao in 2001 and is headquartered in Burlingame, CA. | Chief Tech/Sci/R&D Officer | 2008-12-31 |
Qu Biologics, Inc.
 Qu Biologics, Inc. BiotechnologyHealth Technology Qu Biologics, Inc. develops site specific immunomodulators that aim to restore the body's innate immune system to treat cancer. The firm specializes in ulcerative colitis, Crohn's disease, arthritis, cancer, autoimmune diseases, autoimmune disorders, inflammatory bowel disease, IBD, Site Specific Immunomodulators, immunotherapies, investigational drug, auto-immune, pharmaceuticals, research, inflammation, biotech and clinical trials. The company was founded by Harold David Gunn and Rob Freeman in 2007 and is headquartered in Burnaby, Canada. | Chief Tech/Sci/R&D Officer | - |
| Cci Cancer Control, Inc. | Corporate Officer/Principal | - |
| Initio Medical Group, Inc. | Chief Executive Officer | - |
Premier Diagnostic Center (Vancouver), Inc.
 Premier Diagnostic Center (Vancouver), Inc. Medical/Nursing ServicesHealth Services Part of Premier Diversified Holdings, Inc., Premier Diagnostic Center (Vancouver), Inc. engages in providing, designing and operating advanced nuclear medicine diagnostic imaging services. The private company is based in Vancouver, Canada. The CEO of the Canadian company is Simon Sutcliffe. | Chief Executive Officer | - |
| International Network For Cancer Treatment & Research | Corporate Officer/Principal | - |
| International Cancer Control Congress Association | President | - |
Institute for Health System Transformation & Sustainability
 Institute for Health System Transformation & Sustainability Medical/Nursing ServicesHealth Services Institute for Health System Transformation & Sustainability operates to improve health care systems in British Columbia. Its projects include NeuroDevNet, emergency medicine network, and ministry projects. The company was founded in 2010 and is headquartered in Vancouver, Canada. | Chairman | - |
| ░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
Former positions of Simon Sutcliffe
| Companies | Position | End |
|---|---|---|
| ░░░░░░░░ ░░░░░░░░░░░ ░░░░░░░ ░░░░░░ ░░░░░ | ░░░░░░░░ | ░░░░░░░░░░ |
| ░░ ░░░░░░ ░░░░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░░░░░░░ ░░░░░░ ░░░░░░░░░░ | ░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░░░░ ░░░░░░░░░░ ░░░ ░░░░░░ ░░░░░░░░ | ░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░ ░░░░░░░░ ░░░░░░░░ | ░░░░░░░░░ | ░░░░░░░░░░ |
Training of Simon Sutcliffe
| St Bartholomew's Hospital Medical College | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| PREMIER DIVERSIFIED HOLDINGS INC. | Finance |
| Private companies | 16 |
|---|---|
| British Columbia Cancer Foundation | |
Genome British Columbia
 Genome British Columbia Miscellaneous Commercial ServicesCommercial Services Genome British Columbia invests in and manages genomics and proteomics research projects. It offers services in human health, environment, agriculture, forestry, mining, energy, aquaculture, and fisheries. The company was founded in 2000 and is headquartered in Vancouver, Canada. | Commercial Services |
Michael Smith Foundation for Health Research
 Michael Smith Foundation for Health Research Investment Trusts/Mutual FundsMiscellaneous The Michael Smith Foundation for Health Research operates as a health research funding agency. The non-profit company is based in Vancouver, Canada. Diane Finegood has been the CEO of the Canadian company since 2012. | Miscellaneous |
Canadian Partnership Against Cancer Corp.
 Canadian Partnership Against Cancer Corp. Miscellaneous Commercial ServicesCommercial Services Canadian Partnership Against Cancer initiates and implements cancer control programs. It offers prevention and screening; diagnosis and clinical care; person-centered perspective; research; system performance; knowledge management; and public engagement and outreach. The company is headquartered in Toronto, Canada. | Commercial Services |
BC Cancer Agency
 BC Cancer Agency Medical/Nursing ServicesHealth Services BC Cancer Agency provides healthcare services. The firm serves for hereditary cancer, indigenous cancer care, interpreters, and psychiatry. Its services include assessment and follow-up library, nutrition services, pain and symptom management, patient and family counselling, PET functional imaging, primary care, screening programs, and speech-language pathology. The company was founded on November 5, 1938 and is headquartered in Vancouver, Canada. | Health Services |
| Princess Margaret Hospital | |
| Ontario Cancer Institute | |
Omnitura Therapeutics, Inc.
Omnitura Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Omnitura Therapeutics, Inc. is a biopharmaceutical company engaged in the commercialization of Multifunctional Multitargeted pharmaceuticals for oncology, a new class of therapies that is design to address the fundamentally complex and heterogeneous nature of cancer. The firm's product Aneustat, is a non-toxic, orally delivered, multivalent I-O drug candidate design to intercept, treat, and prevent cancer. The company was founded by James Dao and Jeffrey Dao in 2001 and is headquartered in Burlingame, CA. | Health Technology |
Institute for Health System Transformation & Sustainability
Institute for Health System Transformation & Sustainability Medical/Nursing ServicesHealth Services Institute for Health System Transformation & Sustainability operates to improve health care systems in British Columbia. Its projects include NeuroDevNet, emergency medicine network, and ministry projects. The company was founded in 2010 and is headquartered in Vancouver, Canada. | Health Services |
Premier Diagnostic Center (Vancouver), Inc.
Premier Diagnostic Center (Vancouver), Inc. Medical/Nursing ServicesHealth Services Part of Premier Diversified Holdings, Inc., Premier Diagnostic Center (Vancouver), Inc. engages in providing, designing and operating advanced nuclear medicine diagnostic imaging services. The private company is based in Vancouver, Canada. The CEO of the Canadian company is Simon Sutcliffe. | Health Services |
| International Cancer Control Congress Association | |
| International Network For Cancer Treatment & Research | |
Qu Biologics, Inc.
Qu Biologics, Inc. BiotechnologyHealth Technology Qu Biologics, Inc. develops site specific immunomodulators that aim to restore the body's innate immune system to treat cancer. The firm specializes in ulcerative colitis, Crohn's disease, arthritis, cancer, autoimmune diseases, autoimmune disorders, inflammatory bowel disease, IBD, Site Specific Immunomodulators, immunotherapies, investigational drug, auto-immune, pharmaceuticals, research, inflammation, biotech and clinical trials. The company was founded by Harold David Gunn and Rob Freeman in 2007 and is headquartered in Burnaby, Canada. | Health Technology |
| Initio Medical Group, Inc. | |
| Cci Cancer Control, Inc. | |
Bold Therapeutics, Inc.
 Bold Therapeutics, Inc. BiotechnologyHealth Technology Bold Therapeutics, Inc. is a Canadian clinical-stage biopharmaceutical company that was founded in 2018 by a team of industry veterans to develop and commercialize novel therapeutics. The company is based in Vancouver, Canada. The company's focus is on developing Bold-100, a drug that has the potential to significantly improve outcomes in a wide range of both solid and liquid tumors in combination with other anticancer therapies. Edward Russell McAllister has been the CEO of the company since 2018. | Health Technology |
- Stock Market
- Insiders
- Simon Sutcliffe
